The plasma nanoDSF denaturation profiles predict the presence of breast cancer
We reveal the potential of nanoDSF and AI applied to plasma samples to discriminate between BC patients and HC. If these results are confirmed, such approach could represent a minimally-invasive, low risk, quick and low-cost technique, which could help to improve the screening of BC.
Authors
- Jihane Pakradouni (ORCID: https://orcid.org/0000-0003-0400-6007)
- Carole Tarpin (ORCID: https://orcid.org/0009-0003-9806-9662)
- Émilie Mamessier (ORCID: https://orcid.org/0000-0002-3516-0093)
- Didier Bechlian
- Rémi Eyraud (ORCID: https://orcid.org/0000-0002-5728-4759)
- Jean‐Marie Boher (ORCID: https://orcid.org/0000-0002-5395-839X)
- François Devred (ORCID: https://orcid.org/0000-0001-5990-8898)
- Alexandre Giraudo
- Philipp O. Tsvetkov (ORCID: https://orcid.org/0000-0002-8622-8836)
- Pascal Finetti (ORCID: https://orcid.org/0000-0002-2674-3123)
- François Bertucci (ORCID: https://orcid.org/0000-0002-0157-0959)
- Mathilde Guérin
- Anthony Gonçalves (ORCID: https://orcid.org/0009-0009-9335-6447)
- Aymen Hassin
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Aix-Marseille Université (FR)
- Laboratoire Hubert Curien (FR)
- Institut de Neurophysiopathologie (FR)
- Centre de Recherche en Cancérologie de Marseille (FR)
- Institut Paoli-Calmettes (FR)
- Université Jean Monnet (FR)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1186/s12967-025-07499-8
- Primary Topic
- MRI in cancer diagnosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00